These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 7908442)

  • 1. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis.
    Williams RO; Mason LJ; Feldmann M; Maini RN
    Proc Natl Acad Sci U S A; 1994 Mar; 91(7):2762-6. PubMed ID: 7908442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha/anti-CD4 therapy.
    Williams RO; Marinova-Mutafchieva L; Feldmann M; Maini RN
    J Immunol; 2000 Dec; 165(12):7240-5. PubMed ID: 11120857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.
    Williams RO; Feldmann M; Maini RN
    Proc Natl Acad Sci U S A; 1992 Oct; 89(20):9784-8. PubMed ID: 1409699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4.
    Williams RO; Ghrayeb J; Feldmann M; Maini RN
    Immunology; 1995 Mar; 84(3):433-9. PubMed ID: 7751027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram.
    Ross SE; Williams RO; Mason LJ; Mauri C; Marinova-Mutafchieva L; Malfait AM; Maini RN; Feldmann M
    J Immunol; 1997 Dec; 159(12):6253-9. PubMed ID: 9550429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term amelioration of established collagen-induced arthritis achieved with short-term therapy combining anti-CD3 and anti-tumor necrosis factor treatments.
    Dépis F; Hatterer E; Lamacchia C; Waldburger JM; Gabay C; Reith W; Kosco-Vilbois M; Dean Y
    Arthritis Rheum; 2012 Oct; 64(10):3189-98. PubMed ID: 22508436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra.
    Joosten LA; Helsen MM; van de Loo FA; van den Berg WB
    Arthritis Rheum; 1996 May; 39(5):797-809. PubMed ID: 8639177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
    Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
    Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies.
    Malfait AM; Williams RO; Malik AS; Maini RN; Feldmann M
    Arthritis Rheum; 2001 May; 44(5):1215-24. PubMed ID: 11352257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human monoclonal rheumatoid factors augment arthritis in mice by the activation of T cells.
    Ezaki I; Okada M; Yoshikawa Y; Fujikawa Y; Hashimoto M; Otsuka M; Nomura T; Yamamoto K; Watanabe T; Shingu M; Nobunaga M
    Clin Exp Immunol; 1996 Jun; 104(3):474-82. PubMed ID: 9099933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study into the mechanisms of action of anti-tumor necrosis factor alpha, anti-CD4, and combined anti-tumor necrosis factor alpha/anti-CD4 treatment in early collagen-induced arthritis.
    Marinova-Mutafchieva L; Williams RO; Mauri C; Mason LJ; Walmsley MJ; Taylor PC; Feldmann M; Maini RN
    Arthritis Rheum; 2000 Mar; 43(3):638-44. PubMed ID: 10728758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease.
    Maini RN; Elliott MJ; Brennan FM; Williams RO; Chu CQ; Paleolog E; Charles PJ; Taylor PC; Feldmann M
    Immunol Rev; 1995 Apr; 144():195-223. PubMed ID: 7590814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis.
    Butler DM; Malfait AM; Maini RN; Brennan FM; Feldmann M
    Eur J Immunol; 1999 Jul; 29(7):2205-12. PubMed ID: 10427983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of a newly established transgenic model of chronic arthritis with nondepleting anti-CD4 monoclonal antibody.
    Mauri C; Chu CQ; Woodrow D; Mori L; Londei M
    J Immunol; 1997 Nov; 159(10):5032-41. PubMed ID: 9366431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation.
    Joosten LA; Helsen MM; Saxne T; van De Loo FA; Heinegard D; van Den Berg WB
    J Immunol; 1999 Nov; 163(9):5049-55. PubMed ID: 10528210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effects of antibodies to tumor necrosis factor-alpha, interleukin-6 and cytotoxic T-lymphocyte antigen 4 immunoglobulin in mice with glucose-6-phosphate isomerase induced arthritis.
    Matsumoto I; Zhang H; Yasukochi T; Iwanami K; Tanaka Y; Inoue A; Goto D; Ito S; Tsutsumi A; Sumida T
    Arthritis Res Ther; 2008; 10(3):R66. PubMed ID: 18534002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody.
    Horneff G; Burmester GR; Emmrich F; Kalden JR
    Arthritis Rheum; 1991 Feb; 34(2):129-40. PubMed ID: 1994909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis.
    Camussi G; Lupia E
    Drugs; 1998 May; 55(5):613-20. PubMed ID: 9585859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of anti-CD4 antibody treatment on inflammatory arthritis in MRL-lpr/lpr mice.
    Gilkeson GS; Spurney R; Coffman TM; Kurlander R; Ruiz P; Pisetsky DS
    Clin Immunol Immunopathol; 1992 Aug; 64(2):166-72. PubMed ID: 1353712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.